Skip to main content
Premium Trial:

Request an Annual Quote

RNA Editing Startup Amber Bio Raises $26M in Seed Funding

NEW YORK — Startup Amber Bio, which is developing a novel RNA editing technology for therapeutic applications, said on Thursday that it has raised $26 million in an oversubscribed seed financing round.

The round was co-led by Playground Global and Andreessen Horowitz Bio + Health, with participation from Eli Lilly, Retinal Degeneration Fund, Hummingbird Ventures, and Pillar VC.

Amber Bio was founded by researchers from the Broad Institute and the University of California, Berkeley to advance a technology that enables multi-kilobase edits to RNA for the treatment of genetic diseases with high allelic diversity.

"There are over 5,000 genetic disorders, many of which are caused by hundreds to thousands of mutations … in genes, leading to disease," Amber Bio Cofounder and Chief Technology Officer Basem Al-Shayeb said in a statement.

"Current gene editing technologies rely on creating solutions on a per-mutation basis, but treating one mutation at a time is not scalable across a patient population," he added. "Our technical approach leverages novel, iteratively engineered Cas-based systems for durable RNA editing, creating significant advantages over editing DNA, which can lead to permanent, off-target mutations."

San Francisco-based Amber Bio said it is working on in-house genetic medicine programs, but did not provide specific details about these efforts.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.